TYENNE

(Tyenne)

Phase 1

FFresenius Kabi Taiwan Ltd.

TYENNE is one of 22 biologic programs targeting Aneurysmal Subarachnoid Hemorrhage. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Aneurysmal Subarachnoid HemorrhageRecruiting

B-Cell Acute Lymphoblastic LeukemiaRecruiting

Aneurysmal Subarachnoid HemorrhagePhase 1

Recruiting

B-Cell Acute Lymphoblastic LeukemiaPreclinical

Recruiting

Competition

Competitive Landscape

28 competitors in B-Cell Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Fludara

8 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

10 4

Blincyto

Amgen

Phase 2

4 5

Tisagenlecleucel

Novartis

Phase 2

1 6

CTL019

Novartis

Phase 3

2 7

YK012

EExcyte Biopharma Ltd

Phase 2

1 8

Erbitux

IImclone

Phase 1

1 9

Actemra

Roche

Preclinical

1 10

Inaticabtagene Autoleucel

JJuventas Cell Therapy Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Aneurysmal Subarachnoid Hemorrhage

NCT06863480

Q4 2033

PreclinicalRecruiting

B-Cell Acute Lymphoblastic Leukemia

NCT07570173

Clinical

Trials by Indication[1]

B-cell acute lymphoblastic leukemia1 trial

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07570173·340 enrolled

Aneurysmal Subarachnoid Hemorrhage1 trial

THRIVE: Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

Recruiting·UUniversity of Florida·Phase 1·NCT06863480·30 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 5, 2024

TYENNE

BLA BLA761275

Mar 14, 2025

TYENNE

BLA BLA761449

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tyenne. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tyenne compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tyenne. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761449). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Fresenius Kabi Taiwan Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: FFresenius Kabi Taiwan Ltd.

TYENNE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2033

Trials by Indication[1]

B-cell acute lymphoblastic leukemia1 trial

Aneurysmal Subarachnoid Hemorrhage1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News